Related Experiment Video
Updated: Mar 8, 2026
Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies
Published on: July 3, 2025
Androgen Receptor Expression in Endometrial Stromal Sarcoma: Correlation With Clinicopathologic Features
Maitrayee Roy1, Sunesh Kumar, Neerja Bhatla
1Departments of Pathology (M.R., D.J., R.P.) Obstetrics and Gynecology (S.K., N.B.) Surgical Oncology, Medical Oncology (L.K.); Dr. B.R. Ambedkar Institute Rotary Cancer Hospital (M.D.R.) Pathology (S.R.M.), All India Institute of Medical Sciences, New Delhi, India.
Androgen receptor (AR) expression is common in low-grade endometrial stromal sarcoma (ESS) but less frequent in high-grade ESS. Further research is needed to determine if AR status can guide hormonal therapy for ESS patients.
Area of Science:
- Gynecologic Oncology
- Pathology
- Endocrinology
Background:
- Endometrial stromal sarcoma (ESS) is a rare uterine malignancy.
- ESSs typically express estrogen receptor (ER) and progesterone receptor (PR).
- The role of androgen receptor (AR) in ESS is not well-defined.
Purpose of the Study:
- To investigate AR expression in ESS.
- To correlate AR, ER, and PR expression with clinicopathologic features.
- To compare AR expression in low-grade ESS (LGESS) versus high-grade ESS (HGESS).
Main Methods:
- Retrospective review of 25 ESS tumor samples from 24 patients.
- Immunohistochemistry for ER, PR, and AR.
- Correlation of receptor expression with tumor grade and patient age.
Main Results:
- Patients in this study, particularly with HGESS, were younger than reported in global literature.
- ER, PR, and AR were expressed in 93.3%, 80%, and 73.3% of LGESSs, respectively.
- In contrast, 50% of HGESSs exhibited a triple-negative hormonal profile, with lower AR, ER, and PR expression compared to LGESS.
Conclusions:
- AR expression is more prevalent in LGESS than HGESS.
- The triple-negative hormonal profile is more common in HGESS.
- The potential role of AR status in guiding adjuvant hormonal therapy for ESS warrants further investigation.
